Showing results (11-20 of 177) with videos related to
Sort By:
Pageof 18
ALTEX|May 29, 2024
The road to virtual control groups and the importance of proper body-weight selectionAlexander Gurjanov, Lea A I Vaas, Thomas Steger-HartmannChemical Research in Toxicology|April 20, 2025
Data Exploration for Target Predictions Using Proprietary and Publicly Available Data SetsAljoša Smajić, Thomas Steger-Hartmann, Gerhard F Ecker, et al.Journal of Magnetic Resonance Imaging : JMRI|November 26, 2009
Gadolinium-based contrast agents and NSF: evidence from animal experienceMartin A Sieber, Thomas Steger-Hartmann, Philipp Lengsfeld, et al.Investigative Radiology|April 21, 2006
Preclinical safety assessment of Vasovist (Gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiographyThomas Steger-Hartmann, Philip B Graham, Simone Müller, et al.Toxicology Reports|October 1, 2017
Value of shared preclinical safety studies - The eTOX databaseKatharine Briggs, Chris Barber, Montserrat Cases, et al.Water Research|January 5, 2002
Investigations into the environmental fate and effects of iopromide (ultravist), a widely used iodinated X-ray contrast mediumThomas Steger-Hartmann, Reinhard Länge, Hermann Schweinfurth, et al.Environmental Toxicology and Chemistry|May 28, 2009
Effects of synthetic gestagens on fish reproductionJana Zeilinger, Thomas Steger-Hartmann, Edmund Maser, et al.Investigative Radiology|July 21, 2010
A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosisThomas Steger-Hartmann, Rainer Hofmeister, Rainer Ernst, et al.Regulatory Toxicology and Pharmacology : RTP|February 24, 2024
Replacing concurrent controls with virtual control groups in rat toxicity studiesAlexander Gurjanov, Carlos Vieira-Vieira, Julia Vienenkoetter, et al.Drug Discovery Today|May 27, 2023
Perspectives of data science in preclinical safety assessmentThomas Steger-Hartmann, Annika Kreuchwig, Ken Wang, et al.Pageof 18